Hepatitis C virus (HCV) is a common cause for chronic inflammation of the liver. Approx. 3% of the world population is currently chronically infected with HCV. Serious complications are cirrhosis and liver cancer, which may appear after 15-20 years. Current drugs used cure about 50% of those treated.
We have generated human monoclonal antibodies to HCV and are studying if these can be given as complement to current medical treatment, and also what characterize efficient anti-viral antibodies. The studies will also provide guidance on how to compose a vaccine to HCV.